New genetic tests enter the market every day, often without clinical and economic evidence to support their use. As a result, health plans are unlikely to extend coverage, and providers are less likely to order the tests. Thus, the success of precision medicine will be determined, in part, by health plan coverage decisions.
Download this white paper to:
Make informed genetic testing coverage decisions—read “Systematic evaluation of genetic tests: finding the intersection of analytic validity, clinical validity, and clinical utility.”
Complete the form and click submit.
*Indicates required fields